Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: Alendronate and risedronate

Journal of Bone and Mineral Metabolism

Volumn 25, Issue 5, 2007, Pages 302-309

  Kamatari, Masayuki ^a,c   Koto, Shiro ^b   Ozawa, Nobuhiro ^b   Urao, Chie ^a   Suzuki, Yumiko ^a   Akasaka, Eri ^a   Yanagimoto, Kae ^a   Sakota, Kazumi ^a  

^a Maruzen Pharmaceuticals Co   (Japan)

^b Internal Medicine Clinic   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Compliance; Osteoporosis; Persistence; Quality of life

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

AGED; ARTICLE; DRUG COST; DRUG INDUCED HEADACHE; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE FACILITY; HEART BEAT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OSTEOPOROSIS; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATIC DISEASE; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALENDRONATE; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; LOGISTIC MODELS; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548018512     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-007-0768-6     Document Type: Article

References (46)

1. RD Chapurlat PD Delmas 2006 Drug insight: bisphosphonates for postmenopausal osteoporosis Nat Clin Pract Endocrinol Met 2 211 219
2. K Kushida M Shiraki T Nakamura H Kishimoto H Morii K Yamamoto K Kaneda M Fukunaga T Inoue M Nakashima H Orimo 2004 Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study J Bone Miner Metab 22 462 468
3. UA Liberman SR Weiss J Broll HW Minne H Quan NH Bell J Rodriguez-Portales RW Downs Jr J Dequeker M Favus 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Eng J Med 333 1437 1443
4. DM Black SR Cummings DB Karpt JA Cauley DE Tompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541
5. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures JAMA 280 2077 2082
6. KE Ensrud DM Black L Palermo DC Bauer E Barrett-Connor SA Quandt DE Thompson DB Karpf 1997 Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial Arch Intern Med 157 2617 2624
7. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut 3rd J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis JAMA 282 1344 1352
8. JY Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Rounagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 83 91
9. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier YJ Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly woman N Eng J Med 344 333 340
10. JMS Macedo CRB Macedo H Elkis IRD Oliveira 1998 Meta-analysis about the efficacy of anti-resorptive drugs in postmenopausal osteoporosis J Clin Parm Ther 23 345 352
11. A Cranney G Guyatt L Griffith G Wells P Tugwell C Rosen 2002 Summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 570 576
12. SE Andrade AM Walker LK Gottlieb NK Hollenberg MA Testa GM Saperia R Platt 1995 Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in a primary care setting? N Eng J Med 332 1125 1131
13. B McClung M McClung 2001 Pharmacologic therapy for the treatment and prevention of osteoporosis Nurs Clin North Am 36 433 440
14. I Tanaka K Hayakawa H Oshima 2003 Tolerance of alendronate in patients with osteoporosis (in Japanese) Osteoporosis Japan 11 252 255
15. B Hamilton K McCoy H Taggart 2003 Tolerability and compliance with risedronate in clinical practice Osteoporos Int 14 259 262
16. RA Yood S Emani JI Reed BE Lewis M Charpentier E Lydick 2003 Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 965 968
17. JJ Caro KJ Ishak KF Huybrechts G Raggio N Chistel 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008
18. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 8 1009 1012
19. DH Solomon J Avorn JN Katz JS Finkelstein M Arnold JM Polinski MA Brookhart 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419
20. JA Cramer S Silverman 2006 Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem Am J Med 119 S12 17
21. P Sambrook 2006 Compliance with treatment in osteoporosis patients Aust Fam Physician 35 3 135 137
22. MP Ettinger R Gallagher PE MacCosbe 2006 Medication persistence with weekly versus daily doses of orally administered bisphosphonates Endocr Pract 12 5 522 528
23. JC Lo AR Pressman MA Omar B Ettinger 2006 Persistence with weekly alendronate therapy among postmenopausal women Osteoporos Int 17 922 928
24. N Miyakoshi E Itoi M Kobayashi H Komada 2003 Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis Osteoporos Int 14 1007 1012
25. K Kushida M Fukunaga H Kishimoto M Shiraki A Itabashi T Inoue K Kaneda H Morii H Nawata K Yamamoto Y Ohashi H Orimo 2004 A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial J Bone Miner Metab 22 469 478
26. E Romagnoli V Carnevale I Nofroni E D'Erasmo F Paglia SD Geronimo J Pepe N Raejntoph M Maranghi S Minisola 2004 Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fractures Osteoporos Int 15 975 980
27. K Yoh K Tanaka A Ishikawa T Ishibashi Y Uchino Y Sato M Tobinaga N Hasegawa S Kamae M Yoshizawa 2005 Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment J Bone Miner Metab 23 167 173
28. AN Tosteson CS Hammond 2002 Quality-of-life assessment in osteoporosis: health-status and preference-based measures Pharmacoeconomics 20 289 303
29. H Takahashi C Iwaya K Iba I Gorai T Suzuki Y Hayashi S Hujinawa K Yamasaki N Endo 2001 The Japanese Osteoporosis QOL Questionnaire (JOQOL): 2000 edition (in Japanese) J Jpn Soc Bone Miner Res 18 83 100
30. H Ohbayashi H Yamase 2004 Efficacy of alendronate (Bonalon) in improving the quality of life of elderly Japanese patients with primary osteoporosis Osteoporosis Jpn 12 369 376
31. K Yamaoka T Tanigawara T Nakagawa T Uno 1981 A pharmacokinetic analysis program (MULTI) for microcomputer J Pharmacobio-dyn 4 879 885
32. S Aki N Eskiyurt U Akarirmak F Tuzun M Eryavuz S Alper O Arpacioglu F Atalay V Kavuncu S Kokino O Kuru K Nas O Ozerbil G Savas OF Sendur D Soy G Akyuz 2003 Gastrointestinal side-effect profile due to the use of alendronate in the treatment of osteoporosis Yonsei Med J 44 961 967
33. FL Lanza RH Hunt AB Thomson JM Provenza MA Blank 2000 Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal woman Gastroenterology 119 631 638
34. E Segal A Tamir S Ish-Shalom 2003 Compliance of osteoporotic patients with different treatment regimens Isr Med Assoc J 5 12 859 862
35. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 9 1453 1460
36. BJ Gertz SD Holland WF Kline BK Matuszewski A Freeman H Quan KC Lasseter JC Mucklow AG Porras 1995 Studies of the oral bioavailability of alendronate Clin Pharmacol Ther 58 288 298
37. DY Mitchell WH Barr RA Eusebio KA Stevens FP Duke DA Russell JD Nesbitt JH Powell GA Thompson 2001 Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration Pharm Res 18 166 170
38. PP Major A Lipton J Berenson G Hortobagyi 2000 Oral bisphosphonates Cancer 88 6 14
39. PD Delmas E Confavreux P Garnero E Confavreux P Garnero G Genolet G Gibelin J Yates 2001 Can alendronate be taken before lunch or dinner? A randomized trial in osteoporotic women J Bone Miner Rest 16 Suppl 1 S406
40. DY Mitchell MA Heise KA Pallone ME Clay JD Nesbitt DA Russell CM Melson 1999 The effect of dosing regimen on the pharmacokinetics of risedronate Br J Clin Pharmacol 48 536 542
41. M Kamatari N Kataoka Y Watanabe M Tsuri Y Fukuda S Koto 2006 Preference survey among osteoporotic patients with bisphosphonate treatment: once-daily and once-weekly dosing (in Japanese) Osteoporosis Jpn 14 4 765 768
42. JA Simon EM Lewiecki ME Smith RA Petruschke L Wang JJ Palmisano 2002 Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, crossover study Clin Ther 24 11 1871 1886
43. D Kendler AWC Kung GE Fuleihan JGG Gonzalez KA Gaines N Verbruggen ME Melton 2004 Patients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 243 251
44. B Ettinger DM Black BH Mitlak RK Knickerbocker T Nickelsen HK Genant C Christiansen PD Delmas JR Zanchetta J Stakkestad CC Gluer K Krueger FJ Cohen S Eckert KE Ensrud LV Avioli P Lips SR Cummings 1999 Multiple outcomes of raloxifene evaluation (MORE) investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637 645
45. EG Lufkin M Wong C Deal 2001 The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis Rheum Dis Clin N Am 27 163 185
46. TW Downey SH Foltz SJ Boccuzzi MA Omar KH Kahler 2006 Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting South Med J 99 6 570 575